GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Cyclically Adjusted FCF per Share

Nuvalent (Nuvalent) Cyclically Adjusted FCF per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Nuvalent's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was $-1.713. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-02), Nuvalent's current stock price is $ 70.65. Nuvalent's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was $0.00. Nuvalent's Cyclically Adjusted Price-to-FCF of today is .


Nuvalent Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Nuvalent's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvalent Cyclically Adjusted FCF per Share Chart

Nuvalent Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
- - - - -

Nuvalent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuvalent's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Nuvalent's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvalent's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvalent's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nuvalent's Cyclically Adjusted Price-to-FCF falls into.



Nuvalent Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nuvalent's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.713/129.4194*129.4194
=-1.713

Current CPI (Dec. 2023) = 129.4194.

Nuvalent does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Nuvalent  (NAS:NUVL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Nuvalent Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Nuvalent's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvalent (Nuvalent) Business Description

Industry
Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Executives
Matthew Shair director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deborah Ann Miller officer: Chief Legal Officer C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Darlene Noci officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Alexandra Balcom officer: Chief Financial Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Christopher Durant Turner officer: Chief Medical Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Mgmt L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. director, 10 percent owner, other: Director by Deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael L. Meyers director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Emily Conley director C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson director C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James Richard Porter director, officer: President and CEO ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142